GDTC

CytoMed Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing cell-based immunotherapies for cancer treatment. The company specializes in gamma-delta T cell therapies, a unique approach to harnessing the immune system to target cancer cells. CytoMed's proprietary platform enables the development of allogeneic (off-the-shelf) cell therapies that can be administered to multiple patients without the need for patient-specific customization. The company's pipeline includes therapeutic candidates targeting various hematologic and solid tumor malignancies. CytoMed conducts clinical trials to evaluate the safety and efficacy of its investigational therapies in cancer patients.